Summary
Updated Aug 30, 2026
Aziz Mottiwala is President and CEO of RxSight, Inc. (RXST). 4 SEC Form 4 filings on record, most recently on 25 July 2026. Most recent open-market trade: sold $297K of TARS on 19 March 2026. Lifetime open-market sales: $893K.
Recent Transactions
4Every recent SEC Form 4 transaction Aziz Mottiwala has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who have reported open-market trades at the same companies as Aziz Mottiwala. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ilya Goldshleger - $2.88M of RXST open-market activity on record
- Jesse Anderson Corley - $1.01M of RXST open-market activity on record
- Shelley B. Thunen - $727K of RXST open-market activity on record
- Shweta Maniar - $174K of RXST open-market activity on record
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Aziz Mottiwala?
Aziz Mottiwala is a corporate insider, tracked as President and CEO of RxSight, Inc. (RXST). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Aziz Mottiwala submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Aziz Mottiwala been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($893K) across all tracked filings.
Where can I see all of Aziz Mottiwala's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Aziz Mottiwala and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
